Transcriptomic associations of a pre-specified 468-gene redox and xenobiotic-metabolism panel across five neurological disorders, with a published-variant inventory

Five neurological disorders—Alzheimer’s disease (AD), autism spectrum disorder (ASD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS)—have distinct clinical and pathological features. I performed independent within-disease random-effects meta-analyses of public transcriptomic cohorts using an immutable 468-gene redox, metal-homeostasis, xenobiotic-metabolism, and barrier panel, and separately inventoried published variants in panel genes for AD, PD and ASD. AD brain, ALS spinal cord/motor neuron, and MS white matter showed disease-specific patterns; in bulk PD substantia nigra two external cohorts supported the high-confidence set in direction and rank but not in per-gene significance. Across the four adult neurodegenerative analyses, 53 genes met the locked high-confidence rule in at least two analyses (Online Resource 3). Seven genes—AKR1C3, CBS, CP, FTL, HMOX1, PINK1, and SLC40A1—met that rule in at least three; CBS was up in AD and PD and down in MS, so the rule does not imply uniform direction or a shared mechanism. HMOX1 was positive in several adult analyses; GSS and GSR transcripts were lower in AD and PD. Adult ASD postmortem brain was a robust FDR null (1 of 392 genes analyzable in at least two cohorts; that gene did not meet the high-confidence rule). Cell-type datasets in MS and PD supply compartment context only. A competitive gene-label permutation test did not show that the 468-gene panel out-enriched power-matched random sets. Inference is gene-level within the locked list, not list-level enrichment. Published variants in panel genes are inventoried for AD, PD and ASD (35 cited entries in the companion manuscripts); they are context for proposed research constructs, not clinical risk scores.

Authors

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11800620/v1
Primary Topic
Alzheimer's disease research and treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Transcriptomic associations of a pre-specified 468-gene redox and xenobiotic-metabolism panel across five neurological disorders, with a published-variant inventory

Mark E. McCaulley
2 links
Research Square
Alzheimer's disease research and treatments
preprint

Transcriptomic associations of a pre-specified 468-gene redox and xenobiotic-metabolism panel across five neurological disorders, with a published-variant inventory

Mark E. McCaulley
preprint en

Abstract

Five neurological disorders—Alzheimer’s disease (AD), autism spectrum disorder (ASD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS)—have distinct clinical and pathological features. I performed independent within-disease random-effects meta-analyses of public transcriptomic cohorts using an immutable 468-gene redox, metal-homeostasis, xenobiotic-metabolism, and barrier panel, and separately inventoried published variants in panel genes for AD, PD and ASD. AD brain, ALS spinal cord/motor neuron, and MS white matter showed disease-specific patterns; in bulk PD substantia nigra two external cohorts supported the high-confidence set in direction and rank but not in per-gene significance. Across the four adult neurodegenerative analyses, 53 genes met the locked high-confidence rule in at least two analyses (Online Resource 3). Seven genes—AKR1C3, CBS, CP, FTL, HMOX1, PINK1, and SLC40A1—met that rule in at least three; CBS was up in AD and PD and down in MS, so the rule does not imply uniform direction or a shared mechanism. HMOX1 was positive in several adult analyses; GSS and GSR transcripts were lower in AD and PD. Adult ASD postmortem brain was a robust FDR null (1 of 392 genes analyzable in at least two cohorts; that gene did not meet the high-confidence rule). Cell-type datasets in MS and PD supply compartment context only. A competitive gene-label permutation test did not show that the 468-gene panel out-enriched power-matched random sets. Inference is gene-level within the locked list, not list-level enrichment. Published variants in panel genes are inventoried for AD, PD and ASD (35 cited entries in the companion manuscripts); they are context for proposed research constructs, not clinical risk scores.

Research Square
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Transcriptomic associations of a pre-specified 468-gene redox and xenobiotic-metabolism panel across five neurological disorders, with a published-variant inventory — Mark E. McCaulley · Research Square (2026) | TGRS Research Map | TGRS